Every material Form 8-K abrdn Life Sciences Investors filed with the SEC in 2012, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
H&Q Life Sciences Investors said its Board of Trustees authorized a renewal of the Fund's share repurchase program. The renewed program would let the Fund buy up to 12% of its outstanding common shares in the open market for one year, starting July 11, 2012, after the current program ends on July 10, 2012. The Board said the aim is to increase net asset value per share and possibly narrow the discount between market price and net asset value.
Renewed program allows open-market purchases of up to 12% of outstanding common shares
Current program runs through July 10, 2012; renewal covers the one-year period beginning July 11, 2012
Repurchase amount and timing are at the discretion of Hambrecht & Quist Capital Management LLC, the Fund's adviser
The filing states there is no assurance shares will be bought at any specific discount or amount, or that market price will rise
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every abrdn Life Sciences Investors filing is on SEC EDGAR ↗. 8-K briefs of other companies →